About Dario Doller
Dario Doller is an executive officer, director and promoter at Modulate Bio.
Dario Doller first appears on SEC filings in 2024.
Experience
This experience comes from Dario Doller's profile and from SEC filings. For roles taken from filings, the years are when the filings name Dario Doller in the role, so the role may have started earlier or lasted longer.
NT
Nabu Therapeutics Current
VP of Medicinal Chemistry
2025 – Present
BB
Babylon Biosciences Current
Discovery Team
2025 – Present
Modulate Bio Inc. Current
Chief Scientific Officer (CSO) (2023 – Present)
Director
2023 – Present · Allston, MA
Develops medicines for people with neurological disorders, including essential tremor and epilepsy.
AS
Alcyoneus ScienceWorks
Early discovery consulting
2015 – 2025
II
iNeuro Therapeutics Inc
VP Chemistry
2022 – 2023
LT
Lucy Therapeutics
VP, Drug Discovery
2021 – 2022
SP
Sunovion Pharmaceuticals
Director, Medicinal Chemistry
2019 – 2021
ST
Sage Therapeutics
Senior Director, Head of Exploratory Research
2017 – 2019
CI
CoNCERT Pharmaceuticals, Inc.
Senior Director, Deuterium Platform
2016 – 2017
LU
Lundbeck
Chemical Biology, Global Head (2011 – 2015)
Director, Medicinal Chemistry (Chemical and Pharmacokinetic Sciences Department) (2006 – 2011)
2006 – 2015
NC
Neurogen Corporation
Associate Director
2000 – 2006
GL
Gliatech
Senior Scientist
1999 – 2000
3P
3-Dimensional Pharmaceuticals
Group Leader
1998 – 1999
SI
Schering-Plough Research Institute
Senior Scientist
1994 – 1998
RH
Rohm and Haas
Research Scientist
1992 – 1994
TU
Texas A&M University
Post-doc
1989 – 1992
Key Colleagues at Startups
The people Dario Doller works with at each company, as listed on that company's latest Form D.
Modulate Bio Inc. · Form D/A, Apr 7, 2026
KH
Kevin Hodgetts
Promoter
AT
Andrew Thomson
President and director